Daptomycin is a cyclic lipopeptide antibiotic: a ring of amino acids with a fatty tail that punctures the membranes of gram-positive bacteria. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and label warnings. Sources were checked on November 17, 2026.
Quick answer: Daptomycin is a prescription lipopeptide antibiotic. Its label covers complicated skin and skin structure infections and S. aureus bloodstream infections. It is not indicated for pneumonia. Label warnings include muscle injury, eosinophilic pneumonia and severe allergic reactions. There is no boxed warning.
Vitrapep does not sell daptomycin; this page is a reference summary of published research and regulatory information.
What is daptomycin?
The Cubicin RF label describes daptomycin as “a cyclic lipopeptide antibacterial agent derived from the fermentation of Streptomyces roseosporus” (Cubicin RF label, 2025). A lipopeptide is a peptide joined to a fat-like chain.
It counts as a peptide because its body is a chain of amino acids. DrugBank text, quoted in PubChem, says it “comprises 13 amino acids, including several non-standard and D-amino acids.” The last 10 amino acids close into a ring. The first amino acid, tryptophan, carries a decanoic acid tail. PubChem lists the formula as C72H101N17O26 and the molecular weight as 1,620.7 g/mol (PubChem CID 21585658). Our peptide primer explains the basics.
Drugs@FDA lists the original approval of Cubicin (NDA 021572) on September 12, 2003, to Cubist Pharmaceuticals (Drugs@FDA). Merck now markets Cubicin RF.
Daptomycin: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic lipopeptide (13 amino acids plus a decanoic acid tail) |
| Class | Lipopeptide antibacterial |
| Molecular formula | C72H101N17O26 |
| Molecular weight | 1,620.7 g/mol |
| First FDA approval | September 12, 2003 (Cubicin, NDA 021572) |
| Brand names (US) | Cubicin, Cubicin RF; generic labels from several makers |
How does daptomycin work?
Daptomycin attacks the bacterial cell membrane, not the cell wall. The label states: “Daptomycin binds to bacterial cell membranes and causes a rapid depolarization of membrane potential.” That loss of potential halts DNA, RNA and protein synthesis, and the cell dies (Cubicin RF label, 2025).
Calcium matters here. The NCI Thesaurus, quoted in PubChem, says the membrane depolarization is “due to calcium-dependant potassium efflux.” In plain terms, potassium leaks out of the cell and its membrane charge collapses. MeSH describes it as an antibiotic “that inhibits gram-positive bacteria.” Compare this with vancomycin, which blocks cell-wall building.
What is daptomycin approved for?
The Cubicin RF label lists these indications:
- complicated skin and skin structure infections (cSSSI) in adults and in children 1 to 17 years old, caused by susceptible gram-positive bacteria;
- Staphylococcus aureus bloodstream infections (bacteremia) in adults; and
- S. aureus bloodstream infections in children 1 to 17 years old.
The label also sets limits. It states that Cubicin RF “is not indicated for the treatment of pneumonia.” It is also not indicated for left-sided infective endocarditis due to S. aureus. It is not recommended in children younger than 1 year.
What did the key trials show?
Bacteremia and endocarditis. The pivotal human trial was a randomized, open-label, multinational study of S. aureus bacteremia and endocarditis. It randomized 246 patients: 124 to daptomycin and 122 to standard therapy. Standard therapy was an antistaphylococcal penicillin or vancomycin, with initial gentamicin. The primary end point was treatment success 42 days after the end of therapy.
Success was 44.2% (53 of 120) with daptomycin and 41.7% (48 of 115) with standard therapy. The difference was 2.4 percentage points (95% CI, −10.2 to 15.1). Clinically significant kidney dysfunction occurred in 11.0% of daptomycin patients and 26.3% of standard therapy patients (P = 0.004). In 6 of 19 daptomycin patients with microbiologic failure, isolates with reduced susceptibility to daptomycin emerged (Fowler et al., 2006). The sponsor’s registry record is NCT00093067.
Skin infections. Two randomized, investigator-blinded trials enrolled 1,092 patients with complicated skin and skin structure infections. The comparators were vancomycin or a semi-synthetic antistaphylococcal penicillin. Clinical success among evaluable patients was 83.4% with daptomycin and 84.2% with comparators (Arbeit et al., 2004). The label adds a pediatric trial that enrolled 396 children, with success of 88% versus 86% at the test-of-cure visit (Cubicin RF label, 2025).
What side effects does the label list?
The Cubicin RF label has no boxed warning. Its highlights list the most common adverse reactions by population:
- Adults with cSSSI: diarrhea, headache, dizziness, rash, abnormal liver tests, elevated CPK, urinary tract infections, hypotension and dyspnea.
- Adults with S. aureus bacteremia or endocarditis: sepsis, bacteremia, abdominal pain, chest pain, edema, throat pain, itching, sweating, insomnia, elevated CPK and hypertension.
- Children: diarrhea, vomiting, abdominal pain, itching, fever, elevated CPK and headache.
CPK is creatine phosphokinase, a marker of muscle injury. The label’s warnings include anaphylaxis, myopathy and rhabdomyolysis, eosinophilic pneumonia, DRESS, tubulointerstitial nephritis, peripheral neuropathy and C. difficile-associated diarrhea. It also warns of decreased efficacy in moderate kidney impairment and of persisting or relapsing S. aureus infection.
Resistance is a concern for the bacteria daptomycin targets. CDC’s 2019 threats report estimated 323,700 MRSA cases in hospitalized U.S. patients in 2017, with 10,600 deaths (CDC, 2019). Reduced daptomycin susceptibility can emerge during treatment, as the Fowler trial showed.
What is daptomycin’s regulatory status, and is it a lab reagent?
Daptomycin is a prescription drug in the United States. A DailyMed search returns 51 daptomycin labels. WHO’s 2024 list of medically important antimicrobials places lipopeptides, including daptomycin, among drugs authorized for use in humans only (WHO, 2024). The labels include Cubicin RF from Merck and generics from makers such as Fresenius Kabi, Camber and Aspiro (DailyMed).
Unlike vancomycin, daptomycin has no documented role as a culture-media reagent in the sources we checked. The research summarized here is clinical: human trials in skin and bloodstream infections.
Frequently asked questions about daptomycin
Is daptomycin a peptide?
Yes. It is a cyclic lipopeptide: 13 amino acids, 10 of them in a ring, with a decanoic acid tail.
When was daptomycin approved?
Drugs@FDA lists the original approval of Cubicin on September 12, 2003.
Is daptomycin approved for pneumonia?
No. The Cubicin RF label states that it “is not indicated for the treatment of pneumonia.”
How is daptomycin different from vancomycin?
Daptomycin disrupts the bacterial membrane. Vancomycin blocks cell-wall building. In the Fowler trial, daptomycin was compared with standard therapy that included vancomycin.
Does daptomycin have a boxed warning?
No. Its warnings include muscle injury, eosinophilic pneumonia, severe allergic reactions and nerve problems.
What to know now
- Structure: cyclic lipopeptide; 13 amino acids plus a decanoic acid tail; 1,620.7 g/mol.
- Approval: Cubicin, September 12, 2003; prescription only.
- Mechanism: binds bacterial membranes and causes rapid depolarization.
- Evidence: 44.2% vs 41.7% success in S. aureus bacteremia; 83.4% vs 84.2% in skin infections.
- Limits: not indicated for pneumonia or left-sided S. aureus endocarditis.
- Safety: no boxed warning; CPK elevation, myopathy and eosinophilic pneumonia are key warnings.
What we’re watching
Further Cubicin RF label revisions on DailyMed, last revised in March 2025. CDC updates on MRSA and other resistant gram-positive bacteria. Related guides: vancomycin and polymyxin B and colistin.